Manufacturing at a Crossroads: Is Your CGT Program Ready for Scale?
Cell and gene therapy (CGT) development is accelerating, but manufacturing remains a key bottleneck. Viral vector production is complex, expensive, and difficult to scale, continuing to pose a major challenge for the industry.
Key Highlights:
- 35% CAGR projected growth in the global CGT market
- Over 2,000 CGT candidates are currently in development
- Up to 50% reduction in upstream costs with stable producer cell lines
Access the Full Article
If you’re a therapy developer, operations leader, or manufacturing strategist, discover how Genezen can help you address cost and scale challenges while maintaining quality and compliance.
Heading to Meeting on the Mesa?
Let’s discuss how Genezen can speed up your journey to the clinic and beyond. Schedule a private meeting with our team to explore strategies for lowering costs, enhancing scalability, and ensuring your CGT program is ready for the market.
